Skip to Main Content

Myriad Genetics Inc

MYGN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
MYGN Income Statement
MYGN Balance Sheet
MYGN Cash Flow

Recent trades of MYGN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
MYGN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
MYGN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
MYGN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by MYGN's directors and management

Government lobbying spending instances

  • $290,000 Oct 17, 2024 Issue: Medicare/Medicaid
  • $290,000 Jul 19, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $290,000 Apr 22, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $290,000 Jan 22, 2024 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $210,000 Oct 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations
  • $210,000 Jul 17, 2023 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
  • $290,000 Jan 20, 2023 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $210,000 Oct 19, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $180,000 Jul 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $290,000 Apr 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $200,000 Jan 20, 2022 Issue: None
  • $160,000 Oct 20, 2021 Issue: None
  • $170,000 Jul 20, 2021 Issue: None
  • $240,000 Apr 20, 2021 Issue: None
  • $210,000 Jan 20, 2021 Issue: None
  • $156,000 Oct 20, 2020 Issue: None
  • $130,000 Jul 20, 2020 Issue: None
  • $220,000 Apr 20, 2020 Issue: None
  • $240,000 Jan 21, 2020 Issue: None
  • $260,000 Oct 21, 2019 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues Budget/Appropriations
  • $170,000 Jul 22, 2019 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $240,000 Apr 22, 2019 Issue: Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark Medicare/Medicaid
  • $230,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark
  • $60,000 Oct 18, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Veterans

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of MYGN in WallStreetBets Daily Discussion

MYGN News

Recent insights relating to MYGN

CNBC Recommendations

Recent picks made for MYGN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MYGN

MYGN Top Shareholders
Shareholder
Shares Held
MYGN Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

MYGN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view MYGN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top